Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy - PubMed (original) (raw)

Comparative Study

doi: 10.1536/ihj.46.231.

Affiliations

• PMID: 15876807
• DOI: 10.1536/ihj.46.231

Free article

Comparative Study

Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy

Kan Zen et al. Int Heart J. 2005 Mar.

Free article

Abstract

We examined the plasma levels of soluble Fas (sFas) or Fas ligand (sFas-L), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) in patients with idiopathic nonobstructive (HNCM) and dilated-phase (DHCM) hypertrophic cardiomyopathy. Patients with idiopathic hypertrophic cardiomyopathy (HCM) may deteriorate to DHCM and the pathogenesis is unknown. The levels of these plasma cytokines were measured by ELISA and echocardiography was performed in 38 HNCM and 11 DHCM patients, and 10 normal subjects. The follow-up period was three years. In HNCM, TNF-alpha (43.3 +/- 45.2 versus 16.9 +/- 4.3 pg/mL) and IL-6 (65.1 +/- 86.4 versus 4.0 +/- 2.1 pg/mL) were slightly higher compared to normal subjects and sFas (3.7 +/- 1.2 versus 2.1 +/- 0.7 ng/mL) increased significantly. sFas (3.9 +/- 1.8), TNF-alpha (79.3 +/- 72.4), and IL-6 (234.1 +/- 135.2) in DHCM were significantly increased and only IL-6 was significantly different from HNCM. sFas-L (0.18 +/- 0.08 versus 0.25 +/- 0.05 ng/mL) in HNCM was significantly decreased, and the decrease was marked in DHCM (0.05 +/- 0.02). In HNCM, TNF-alpha was negatively correlated with fractional shortening (r = -0.432, P = 0.0062) or positively with IL-6 (r = 0.665, P < 0.0001), while sFas-L was negatively correlated with IL-6 (r = -0.580, P < 0.0001). DHCM with high sFas had significantly higher cumulative incidences of worsening heart failure. The Fas/Fas-L system and proinflammatory cytokines may play an important role in the status of HCM and its progression to DHCM.

PubMed Disclaimer

Similar articles

• Comparative study of the roles of cytokines and apoptosis in dilated and hypertrophic cardiomyopathies.
  Buzás K, Megyeri K, Hõgye M, Csanády M, Bogáts G, Mándi Y. Buzás K, et al. Eur Cytokine Netw. 2004 Jan-Mar;15(1):53-9. Eur Cytokine Netw. 2004. PMID: 15217753
• Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure.
  Nishigaki K, Minatoguchi S, Seishima M, Asano K, Noda T, Yasuda N, Sano H, Kumada H, Takemura M, Noma A, Tanaka T, Watanabe S, Fujiwara H. Nishigaki K, et al. J Am Coll Cardiol. 1997 May;29(6):1214-20. doi: 10.1016/s0735-1097(97)00055-7. J Am Coll Cardiol. 1997. PMID: 9137215
• Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure.
  Adamopoulos S, Parissis J, Karatzas D, Kroupis C, Georgiadis M, Karavolias G, Paraskevaidis J, Koniavitou K, Coats AJ, Kremastinos DT. Adamopoulos S, et al. J Am Coll Cardiol. 2002 Feb 20;39(4):653-63. doi: 10.1016/s0735-1097(01)01795-8. J Am Coll Cardiol. 2002. PMID: 11849865 Clinical Trial.
• Proinflammatory cytokine activation is linked to apoptotic mediator, soluble Fas level in patients with chronic heart failure.
  Kinugawa T, Kato M, Yamamoto K, Hisatome I, Nohara R. Kinugawa T, et al. Int Heart J. 2012;53(3):182-6. doi: 10.1536/ihj.53.182. Int Heart J. 2012. PMID: 22790687
• [Dilated form of hypertrophic cardiomyopathy].
  Yamada A, Suzuki H, Kawai S. Yamada A, et al. Nihon Rinsho. 2000 Jan;58(1):102-7. Nihon Rinsho. 2000. PMID: 10885296 Review. Japanese.

Cited by

• Cytokeratin 18 as a Novel Biomarker in Patients with Hypertrophic Cardiomyopathy.
  Fragkiadakis K, Ktena N, Kalantidou A, Dermitzaki E, Anastasiou I, Papathanassiou S, Kontaraki J, Kalomoirakis P, Kanoupakis E, Patrianakos A, Papadomanolakis A, Daskalaki E, Kiousi T, Kouraki K, Kranioti E, Tzardi M, Venihaki M, Karagogeos D, Capetanaki Y, Kardassis D, Kochiadakis G, Parthenakis F, Marketou M. Fragkiadakis K, et al. Cells. 2024 Aug 9;13(16):1328. doi: 10.3390/cells13161328. Cells. 2024. PMID: 39195218 Free PMC article.
• A personalized mRNA signature for predicting hypertrophic cardiomyopathy applying machine learning methods.
  Gu J, Zhao Y, Ben Y, Zhang S, Hua L, He S, Liu R, Chen X, Sheng H. Gu J, et al. Sci Rep. 2024 Jul 24;14(1):17023. doi: 10.1038/s41598-024-67201-8. Sci Rep. 2024. PMID: 39043774 Free PMC article.
• Dapagliflozin mitigates oxidative stress, inflammatory, and histopathological markers of aging in mice.
  Shihab EM, Kadhim HM, Shahooth SS. Shihab EM, et al. J Med Life. 2024 Feb;17(2):157-163. doi: 10.25122/jml-2023-0343. J Med Life. 2024. PMID: 38813367 Free PMC article.
• The Role of Pro-Inflammatory Cytokines in the Pathogenesis of Cardiovascular Disease.
  Zhang H, Dhalla NS. Zhang H, et al. Int J Mol Sci. 2024 Jan 16;25(2):1082. doi: 10.3390/ijms25021082. Int J Mol Sci. 2024. PMID: 38256155 Free PMC article. Review.
• Prognostic value of albumin to fibrinogen ratio for mortality in patients with hypertrophic cardiomyopathy.
  Li L, Ban C, Ruan H, Zhang M, Wang Z, Ma M, Zheng Y, He S. Li L, et al. BMC Cardiovasc Disord. 2023 Nov 16;23(1):559. doi: 10.1186/s12872-023-03562-8. BMC Cardiovasc Disord. 2023. PMID: 37974066 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • J-STAGE, Japan Science and Technology Information Aggregator, Electronic

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal